Transfusion-Dependent β-Thalassemia (TDT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
β-thalassemia are monogenic disorders usually caused by reduced or absent synthesis of the βglobin chain, one of the main components of adult hemoglobin (HbA, α2β2. This results in a relative increase in the unattached αglobin chains (α/β-chain imbalance) that form insoluble Hemi-chromes in the erythrocyte progenitors. The Hemi-chromes damage the erythrocyte membrane, leading to severe intramedullary erythrocyte apoptosis (ineffective erythropoiesis, IE) and severely shortened red blood cell (RBC) life span due to extra-medullary hemolysis, leading to severe anemia.
·
Transfusion-dependent β-thalassemia (TDT) is
the most severe form of the disease, characterized by severe anemia, and
requires lifelong, regular blood transfusions to maintain Hb levels. These
transfusions carry the risk of progressive multi-organ damage due to
unavoidable iron overload.
·
In the USA, the estimated β-thalassemia cases
range between 1.5 to 2.6 cases per 100,000 population. However, it varies based
on geographic presence.
Thelansis’s “Transfusion-Dependent
β-Thalassemia (TDT) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Transfusion-Dependent
β-Thalassemia (TDT) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Transfusion-Dependent β-Thalassemia (TDT) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Transfusion-Dependent β-Thalassemia
(TDT) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment